Trial Profile
Multicenter Open-Label Treatment Protocol to Observe the Safety of Gene-Activated™ Human Glucocerebrosidase (GA-GCB, Velaglucerase Alfa) ERT in Newly Diagnosed or Previously Treated (With Imiglucerase) Patients With Type 1 Gaucher Disease
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Velaglucerase alfa (Primary)
- Indications Gaucher's disease type I
- Focus Adverse reactions; Expanded access
- Sponsors Shire
- 14 Nov 2014 New trial record